TickerFacts.

Bristol Myers Squibb Co (BMY): Long-Term Debt

Annual figures by period end, from SEC filings.

$44.83B
As of 2025-12-31
$42.86B
As of 2026-06-30
+4.8%
3-year compound annual growth
-2.3%
5-year compound annual growth
$50.34B2011-03-31: $5.28B2011-06-30: $5.33B2011-09-30: $5.44B2011-12-31: $5.38B2012-03-31: $5.27B2012-06-30: $5.21B2012-09-30: $7.23B2012-12-31: $7.23B2013-03-31: $7.18B2013-06-30: $7.12B2013-09-30: $6.56B2013-12-31: $7.98B2014-03-31: $7.37B2014-06-30: $7.37B2014-09-30: $7.27B2017-03-31: $7.24B2017-06-30: $6.91B2017-09-30: $6.98B2017-12-31: $6.97B2018-03-31: $5.78B2018-06-30: $5.67B2018-09-30: $5.69B2018-12-31: $6.89B2019-03-31: $5.63B2019-06-30: $24.43B2019-09-30: $24.39B2019-12-31: $46.15B2020-03-31: $46.10B2020-06-30: $46.11B2020-09-30: $44.61B2020-12-31: $50.34B2021-12-31: $44.37B2022-12-31: $38.95B2023-12-31: $39.53B2024-12-31: $49.43B2025-12-31: $44.83B$44.83B
2011-03-31 Long-Term Debt (USD) 2025-12-31
Period endedLong-Term DebtChange YoYSource filing
2025-12-31$44.83B-9.3%2026-02-11, Balance as of period end
2024-12-31$49.43B+25.1%2026-02-11, Balance as of period end
2023-12-31$39.53B+1.5%2025-02-12, Balance as of period end
2022-12-31$38.95B-12.2%2024-02-13, Balance as of period end
2021-12-31$44.37B-11.9%2023-02-14, Balance as of period end
2020-12-31$50.34Bn/a2022-02-09, Balance as of period end
2020-09-30$44.61Bn/a2021-02-10, Balance as of period end
2020-06-30$46.11Bn/a2021-02-10, Balance as of period end
2020-03-31$46.10Bn/a2021-02-10, Balance as of period end
2019-12-31$46.15Bn/a2021-02-10, Balance as of period end
2019-09-30$24.39Bn/a2021-02-10, Balance as of period end
2019-06-30$24.43Bn/a2021-02-10, Balance as of period end
2019-03-31$5.63Bn/a2021-02-10, Balance as of period end
2018-12-31$6.89Bn/a2020-02-24, Balance as of period end
2018-09-30$5.69Bn/a2020-02-24, Balance as of period end
2018-06-30$5.67Bn/a2020-02-24, Balance as of period end
2018-03-31$5.78Bn/a2020-02-24, Balance as of period end
2017-12-31$6.97Bn/a2019-02-25, Balance as of period end
2017-09-30$6.98Bn/a2019-02-25, Balance as of period end
2017-06-30$6.91Bn/a2019-02-25, Balance as of period end
2017-03-31$7.24Bn/a2019-02-25, Balance as of period end
No annual figure between 2014-09-30 and 2017-03-31.
2014-09-30$7.27Bn/a2015-02-13, Balance as of period end
2014-06-30$7.37Bn/a2015-02-13, Balance as of period end
2014-03-31$7.37Bn/a2015-02-13, Balance as of period end
2013-12-31$7.98Bn/a2014-02-14, Balance as of period end
2013-09-30$6.56Bn/a2015-02-13, Balance as of period end
2013-06-30$7.12Bn/a2015-02-13, Balance as of period end
2013-03-31$7.18Bn/a2015-02-13, Balance as of period end
2012-12-31$7.23Bn/a2014-02-14, Balance as of period end
2012-09-30$7.23Bn/a2014-02-14, Balance as of period end
2012-06-30$5.21Bn/a2014-02-14, Balance as of period end
2012-03-31$5.27Bn/a2014-02-14, Balance as of period end
2011-12-31$5.38Bn/a2013-02-15, Balance as of period end
2011-09-30$5.44Bn/a2013-02-15, Balance as of period end
2011-06-30$5.33Bn/a2013-02-15, Balance as of period end
2011-03-31$5.28Bn/a2013-02-15, Balance as of period end

Long-Term Debt at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedLong-Term DebtChange YoY
Bristol Myers Squibb Co (BMY)2025-12-31$44.83B-9.3%
Abbott Laboratories (ABT)2025-12-31$12.93B-8.5%
AbbVie Inc. (ABBV)2025-12-31$64.50B-3.5%
Eli Lilly & Co (LLY)2024-12-31$29.47B+54.3%
Johnson & Johnson (JNJ)2025-12-28$41.44B+27.9%
Bausch Health Companies Inc. (BHC)2025-12-31$20.82B-3.7%
Organon & Co. (OGN)2025-12-31$8.64B-2.7%
BeOne Medicines Ltd. (ONC)2025-12-31$836.37Mn/a
Elanco Animal Health Inc (ELAN)2025-12-31$3.76B-12.9%

Compare BMY, ABT, ABBV, LLY side by side · Screen every company in Pharmaceutical Preparations ↗